ImExHS Limited (AU:IME)
ASX:IME
Top Page
ImExHS Limited
(Sydney:IME)
Select Model
Select Model
Rating:51Neutral
Price Target:
AU$0.37
▼(-7.00% Downside)
Action:ReiteratedDate:03/27/26
The score is primarily driven by mixed financial performance: accelerating revenue growth and a low-debt balance sheet are positives, but ongoing losses, negative returns, and weakened gross margin are significant headwinds. Technical indicators point to soft near-term momentum, and valuation is constrained by negative earnings and no dividend support.
Positive Factors
Recurring SaaS revenue
ImExHS's subscription and licensing model for Hiruko creates durable, recurring revenue and multi-year contract visibility. That business model supports predictable cash inflows, customer stickiness and scalable unit economics over time, helping fund R&D and geographic expansion.
Negative Factors
Ongoing net losses
Continued negative operating and net margins mean ImExHS has yet to convert revenue growth into sustainable profitability. Over time this limits retained earnings, pressures returns on equity, and may force external funding needs that dilute shareholders or constrain long-term reinvestment.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring SaaS revenue
ImExHS's subscription and licensing model for Hiruko creates durable, recurring revenue and multi-year contract visibility. That business model supports predictable cash inflows, customer stickiness and scalable unit economics over time, helping fund R&D and geographic expansion.
Read all positive factors
ImExHS Limited (IME) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$21.63M
Dividend YieldN/A
Average Volume (3M)41.77K
Price to Earnings (P/E)―
Beta (1Y)0.22
Revenue Growth6.77%
EPS Growth-8.45%
CountryAU
Employees400
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)<0.01
Shares Outstanding54,070,730
10 Day Avg. Volume23,052
30 Day Avg. Volume41,775
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)1.29
Price to Sales (P/S)0.71
P/FCF Ratio83.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.50Price Target Upside25.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.02
Revenue Forecast (FY)AU$32.60M
ImExHS Limited Business Overview & Revenue Model
Company Description
ImExHS Limited offers cloud-based medical imaging solutions in Australia and internationally. It offers a medical imaging software that is focused on the development and sale of modular imaging systems, which include information systems for radiol...
How the Company Makes Money
ImExHS Limited generates revenue primarily through the sale and licensing of its proprietary software solutions, including subscription-based models for its Hiruko™ platform. The company charges healthcare providers, hospitals, and pathology labs ...
ImExHS Limited Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
74
Positive
Cash Flow
52
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 28.97M | 26.57M | 19.67M | 17.12M | 13.37M |
| Gross Profit | 8.31M | 11.03M | 3.50M | 3.52M | 5.22M |
| EBITDA | 1.52M | 45.58K | -1.26M | -744.21K | -3.00M |
| Net Income | -2.88M | -2.63M | -4.19M | -3.04M | -4.70M |
Balance Sheet | |||||
| Total Assets | 23.73M | 21.81M | 22.65M | 20.99M | 25.01M |
| Cash, Cash Equivalents and Short-Term Investments | 3.30M | 2.07M | 2.36M | 1.91M | 4.19M |
| Total Debt | 566.32K | 1.19M | 1.29M | 1.12M | 2.40M |
| Total Liabilities | 7.86M | 7.33M | 6.67M | 5.09M | 8.36M |
| Stockholders Equity | 15.87M | 14.47M | 15.98M | 15.90M | 16.65M |
Cash Flow | |||||
| Free Cash Flow | 244.16K | -1.69M | 414.59K | -4.23M | -5.53M |
| Operating Cash Flow | 564.71K | -634.68K | 2.61M | -2.20M | -2.97M |
| Investing Cash Flow | -1.19M | -765.91K | -2.13M | -2.22M | -3.39M |
| Financing Cash Flow | 1.68M | 1.18M | -98.61K | 2.25M | -161.78K |
ImExHS Limited Technical Analysis
Positive
0.40
Price Trends
0.41
Negative
0.38
Positive
0.32
Positive
Market Momentum
>-0.01
Negative
50.65
Neutral
55.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IME, the sentiment is Positive. The current price of 0.4 is above the 20-day moving average (MA) of 0.40, below the 50-day MA of 0.41, and above the 200-day MA of 0.32, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.65 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:IME.
ImExHS Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$21.63M | -7.11 | -19.01% | ― | 6.77% | -8.45% | |
47 Neutral | AU$19.56M | 3.95 | 7.57% | ― | 28.91% | -1050.00% | |
44 Neutral | AU$43.60M | -5.70 | -14.19% | ― | 3.61% | -17.03% | |
43 Neutral | AU$72.67M | -6.64 | -59.96% | ― | ― | ― | |
43 Neutral | AU$31.35M | -3.13 | -1009.84% | ― | 25.98% | 22.10% |
* Healthcare Sector Average
AU:IME
ImExHS Limited
0.40
0.08
25.00%
AU:RHT
Resonance Health Ltd
0.04
<0.01
7.89%
AU:BMT
Beamtree Holdings Ltd
0.15
-0.07
-31.82%
AU:SHG
Singular Health Group Ltd
0.23
0.01
4.55%
AU:PCK
PainChek Ltd
0.15
-0.18
-54.41%
ImExHS Limited Corporate Events
ImExHS Director Updates Equity Interests After Option Lapse
Apr 8, 2026
ImExHS Limited has reported a change in the securities held by director German Arango, detailing the lapse of certain option holdings after vesting conditions were not met. Following the change, Arango retains substantial interests in the company ...
ImExHS Director Increases Direct Shareholding Through Option Exercise
Apr 8, 2026
ImExHS director Douglas Lingard has adjusted his holdings in the company following the exercise of nil‑price options into fully paid ordinary shares. He converted 20,044 options into the same number of shares at no cash consideration, increa...
ImExHS Options Lapse Cuts Potential Future Dilution
Apr 7, 2026
ImExHS Limited has notified the market of the cessation of several tranches of options after the conditions attached to these securities were not met by the specified dates. A total of 1,010,843 options across three series, all with nil exercise p...
ImExHS Seeks Quotation for Additional Ordinary Shares on ASX
Apr 7, 2026
ImExHS Limited has applied for quotation on the ASX of 20,044 additional ordinary fully paid shares, to be issued on 7 April 2026. The new securities arise from the exercise or conversion of existing options or other convertible instruments, margi...
ImExHS lodges updated corporate governance statement and Appendix 4G
Feb 27, 2026
ImExHS Limited has confirmed the lodgement of its corporate governance statement for the financial year ended 31 December 2025, making it accessible via its investor centre website in accordance with ASX Listing Rule 4.10.3. The company has also s...
ImExHS updates corporate governance framework and board oversight roles
Feb 27, 2026
ImExHS Limited has released its updated Corporate Governance Statement as at 27 February 2026, outlining the extent of its compliance with the ASX Corporate Governance Council’s fourth edition principles and recommendations. The document det...
ImExHS Highlights Dual-Business Model to Expand Access to Medical Imaging
Feb 27, 2026
ImExHS Limited outlined its FY25 positioning as a unified company with two complementary business lines dedicated to democratizing access to medical imaging expertise. It highlighted its dual focus on medical imaging software and Colombia-based ra...
IMEXHS Delivers Strong FY25 Growth and Shifts Focus to High-Margin Software
Feb 27, 2026
IMEXHS reported full-year 2025 revenue of $29.0 million, up 10% on the prior year and above guidance, with underlying EBITDA tripling to $1.6 million as recurring revenue, annualised recurring revenue and cash all improved while debt fell. The com...
IMEXHS lifts revenue and asset backing despite ongoing annual loss
Feb 27, 2026
IMEXHS Limited reported a 9.5% increase in revenue to $28.97 million for the year ended 31 December 2025, while its net loss after tax widened slightly to $2.88 million compared with $2.63 million a year earlier. Despite the ongoing losses and the...
IMEXHS sets dates for FY25 results release and investor briefing
Feb 20, 2026
ImExHS Limited has scheduled the release of its FY25 financial results for 27 February 2026, covering the year ended 31 December 2025. The company will follow this with an investor presentation led by CEO and Co-Founder Dr German Arango and CFO Re...
ImExHS Delivers Top-End FY25 Results as Recurring Software Revenue and Partner Deals Accelerate
Jan 30, 2026
ImExHS Limited reported unaudited full-year 2025 results at the top end of its guidance, with revenue rising 10% to $29.0 million and underlying EBITDA more than tripling to $1.6 million, supported by a strong fourth quarter and a 16% increase in ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.